The Seattle Times

STEVE RINGMAN / THE SEATTLE TIMES
Advertising

Friday, November 15, 2013

How a drug for few patients was turned into $81 million in sales

Part 2: Orphan drugs, approved for rare diseases, can become big sellers. Arsenic trioxide, the product of Seattle biotech Cell Therapeutics, provides a case study in how the chase for profits can turn into accusations of unlawful marketing. Cell Therapeutics is headquartered near the Seattle waterfront, just north of Olympic Sculpture Park.